102 related articles for article (PubMed ID: 14634791)
1. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
3. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
4. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone as a probe for vinorelbine clearance.
Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
[TBL] [Abstract][Full Text] [Related]
6. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
8. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Khayat D; Rixe O; Brunet R; Goupil A; Bugat R; Harousseau JL; Ifrah N; Puozzo C
Cancer Chemother Pharmacol; 2004 Sep; 54(3):193-205. PubMed ID: 15160284
[TBL] [Abstract][Full Text] [Related]
12. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.
Kitzen JJ; Puozzo C; de Jonge MJ; Brandely M; Verweij J
Eur J Cancer; 2010 Jan; 46(2):266-9. PubMed ID: 19944596
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.
Nguyen L; Tranchand B; Puozzo C; Variol P
Br J Clin Pharmacol; 2002 May; 53(5):459-68. PubMed ID: 11994051
[TBL] [Abstract][Full Text] [Related]
14. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cisplatin in adult cancer patients.
de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
19. Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Cupissol D; Bressolle F
Cancer Chemother Pharmacol; 2002 Jan; 49(1):48-56. PubMed ID: 11855752
[TBL] [Abstract][Full Text] [Related]
20. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
